Canada Markets closed

Affimed N.V. (AFMD)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
3.0100-0.1400 (-4.44%)
At close: 04:00PM EDT
2.9950 -0.02 (-0.50%)
After hours: 04:05PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close3.1500
Open3.0800
Bid2.9600 x 3200
Ask3.0200 x 2900
Day's Range2.9900 - 3.0900
52 Week Range2.2300 - 7.3500
Volume581,148
Avg. Volume1,005,445
Market Cap449.51M
Beta (5Y Monthly)2.43
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Affimed Reports Second Quarter 2022 Financial Results and Highlights Recent Operational Progress

    AFM13 monotherapy: On track to report topline data of the registration-directed REDIRECT trial in the fourth quarter of 2022AFM13 combination with natural killer (NK) cells: On track to report updated data at a scientific conference in the fourth quarter of 2022AFM24: Studies continue to enroll; data updates expected at scientific conferences in the second half of 2022AFM28: Following interactions with FDA, strategic decision to focus early clinical development in non-U.S. jurisdictions; clinica

  • GlobeNewswire

    Affimed to Report Second Quarter 2022 Financial Results & Corporate Update on August 11, 2022

    HEIDELBERG, Germany, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will release second quarter 2022 results and corporate update on Thursday, August 11, 2022. The Company will host a conference call at 8:30 a.m. Eastern Daylight Time. The conference call will be available via phone and webcast. To access the call,

  • GlobeNewswire

    Affimed Establishes Scientific Advisory Board

    Independent advisory panel to be made up of distinguished, key opinion leaders with scientific and clinical expertise in innate immunity and oncologyScientific Advisory Board to provide guidance on the Company’s development strategy across assets and assessment of emerging technologies HEIDELBERG, Germany, June 30, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to